MYH9: A key protein involved in tumor progression and virus-related diseases - 04/02/24
Abstract |
The myosin heavy chain 9 (MYH9) gene encodes the heavy chain of non-muscle myosin IIA (NMIIA), which belongs to the myosin II subfamily of actin-based molecular motors. Previous studies have demonstrated that abnormal expression and mutations of MYH9 were correlated with MYH9-related diseases and tumors. Furthermore, earlier investigations identified MYH9 as a tumor suppressor. However, subsequent research revealed that MYH9 promoted tumorigenesis, progression and chemoradiotherapy resistance. Note-worthily, MYH9 has also been linked to viral infections, like severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Epstein-Barr virus, and hepatitis B virus, as a receptor or co-receptor. In addition, MYH9 promotes the development of hepatocellular carcinoma by interacting with the hepatitis B virus-encoding X protein. Finally, various findings highlighted the role of MYH9 in the development of these illnesses, especially in tumors. This review summarizes the involvement of the MYH9-regulated signaling network in tumors and virus-related diseases and presents possible drug interventions on MYH9, providing insights for the use of MYH9 as a therapeutic target for tumors and virus-mediated diseases.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | MYH9 can act as a receptor or co-receptor to mediate the entry of some viruses into cells, leading to the corresponding diseases. |
• | MYH9 acts as a tumor suppressor in mouse skin squamous cell carcinoma and melanoma. |
• | MYH9 acts as a tumor promoter in most tumors by activating some classical signaling pathways. |
Keywords : Myosin heavy chain 9, Non-muscle myosin IIA, Tumor, Virus
Plan
Vol 171
Article 116118- février 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?